ArticleJournal of child and adolescent psychopharmacology2026
Long-Acting Injectable Antipsychotics and Time to Readmission in Early Psychosis.
Article in Journal of child and adolescent psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundLong-acting injectable (LAI) antipsychotics have demonstrated benefits in reducing relapse and hospitalization in psychotic disorders, yet their real-world impact in early-phase psychosis remains incompletely understood. This study examined baseline characteristics, hospitalization features, and postdischarge outcomes among young patients with early psychosis treated with LAI versus oral (PO) antipsychotics.
methodsThis retrospective chart review included 229 patients under age 25 hospitalized for psychosis at a multicenter health system between 2018 and 2022. Patients receiving LAI (
resultsThe LAI group was older and exhibited greater clinical and social risk, including more prior hospitalizations, higher rates of undomiciled status, and more suicide attempts. They also had longer inpatient stays and greater medication complexity during hospitalization. One-year readmission rates were similar between groups (30.6% LAI vs. 24.7% PO). Among readmitted patients, the LAI group showed longer time to readmission. In adjusted analyses, LAI treatment was not independently associated with readmission. Undomiciled status was independently associated with readmission, paradoxically in the direction of lower odds.
conclusionsFor young patients with early psychosis, LAIs were preferentially prescribed to higher-risk patients but were not independently associated with reduced 1-year readmission. Comparable outcomes between groups despite greater baseline risk in the LAI cohort suggest that LAIs may partially mitigate elevated risk, though this interpretation requires prospective confirmation. Housing instability emerged as a critical determinant of readmission patterns, underscoring the need for integrated pharmacologic and social interventions in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.